儿童及青少年鼻咽癌的研究进展

doi:10.3760/cma.j.cn371439-20250406-00058

摘要/Abstract

摘要：

鼻咽癌在儿童及青少年中少见，但预后较好，越来越多的研究关注于患者治疗后的生长发育及生命质量。儿童及青少年鼻咽癌的研究取得了一定的进展，涵盖病因、临床特征、治疗方案及预后等多个方面。引起鼻咽癌的因素包括病毒感染、遗传易感性及环境因素等，主要治疗手段有放疗、化疗、靶向治疗、免疫治疗、手术，此外，传统中医药在辅助治疗鼻咽癌方面也显示出其独特的疗效和潜力，为患者提供了更多的治疗选择。进一步探讨影响儿童及青少年鼻咽癌发生的因素，分析不同治疗方法的效果与应用，可为未来的研究提供新的视角与参考。

关键词: 鼻咽肿瘤, 儿童, 青少年, 治疗

Abstract:

Nasopharyngeal carcinoma is rare in children and adolescents， but the prognosis is relatively good. More and more studies focus on the growth and development， as well as the quality of life of patients after treatment. Certain progress has been made in the research of nasopharyngeal carcinoma in children and adolescents， covering multiple aspects such as etiology， clinical characteristics， treatment regimens and prognosis. The factors causing nasopharyngeal carcinoma include viral infection， genetic susceptibility and environmental factors， etc. The main treatment methods are radiotherapy， chemotherapy， targeted therapy， immunotherapy and surgery. In addition， traditional Chinese medicine has also shown its unique efficacy and potential in the adjuvant therapy of nasopharyngeal carcinoma， providing more treatment options for patients. Further exploration of the factors influencing the occurrence of nasopharyngeal carcinoma in children and adolescents， and analysis of the effects and applications of different treatment methods， can provide new perspectives and references for future research.

Key words: Nasopharyngeal neoplasms, Child, Adolescent, Therapy

张彦萍, 薛金才, 辛元春, 刘勤江, 董方. 儿童及青少年鼻咽癌的研究进展[J]. 国际肿瘤学杂志, 2025, 52(6): 337-342.

Zhang Yanping, Xue Jincai, Xin Yuanchun, Liu Qinjiang, Dong Fang. Research progress on nasopharyngeal carcinoma in children and adolescents[J]. Journal of International Oncology, 2025, 52(6): 337-342.

参考文献 66

[1]	王琳, 罗东华, 李阳, 等. 儿童鼻咽癌的治疗进展[J]. 中国癌症防治杂志, 2017, 9(4): 266-272. DOI: 10.3969/j.issn.1674-5671.2017.04.05.
[2]	Person L, Lacour B, Faure L, et al. Childhood head and neck cancer in France: incidence, survival and trends from 2000 to 2015[J]. Int J Pediatr Otorhinolaryngol, 2021, 150: 110858. DOI: 10.1016/j.ijporl.2021.110858.
[3]	Farhat F, Daulay ER, Chrestella J, et al. Correlation of P38 mitogen-activated protein kinase expression to clinical stage in nasopharyngeal carcinoma[J]. Open Access Maced J Med Sci, 2018, 6(11): 1982-1985. DOI: 10.3889/oamjms.2018.355. pmid: 30559847
[4]	Zhang J, Luo X, Huang Q, et al. Clinicopathological and prognostic features of nasopharyngeal carcinoma in children and adolescents: a retrospective study of 196 cases in South China[J]. Int J Cancer, 2021, 148(5): 1087-1096. DOI: 10.1002/ijc.33293.
[5]	Lygina E, Morgacheva D, Khadela A, et al. Effectiveness of metronomic chemotherapy in a child with medulloblastoma: a case report[J]. Oncol Lett, 2023, 25(5): 194. DOI: 10.3892/ol.2023.13780.
[6]	Popov V, Suleyman G, Spasov N, et al. A nine-year-old child with nasopharyngeal cancer treated with concomitant chemoradiotherapy with cisplatin—a case report[J]. Folia Med (Plovdiv), 2024, 66(3): 421-425. DOI: 10.3897/folmed.66.e122593.
[7]	Schultz KAP, Chintagumpala M, Piao J, et al. Rare tumors: opportunities and challenges from the children's oncology group perspective[J]. EJC Paediatr Oncol, 2023, 2: 100024. DOI: 10.1016/j.ejcped.2023.100024.
[8]	Gong T, Liu Y, Jie H, et al. Retrospective analysis of clinical features and prognosis of nasopharyngeal carcinoma in children and adolescents[J]. Front Pediatr, 2022, 10: 939435. DOI: 10.3389/fped.2022.939435.
[9]	Shi Y, Wu Y, He J, et al. Prognosis of nasopharyngeal carcinoma in children and adolescents: a population-based analysis[J]. BMC Pediatr, 2025, 25(1): 40259339. DOI: 10.1186/s12887-025-05653-1.
[10]	Wong EHC, Tan HY, Dompok TM, et al. The first report on incidence of nasopharyngeal carcinoma in Sabah, Borneo[J]. ORL J Otorhinolaryngol Relat Spec, 2021, 83(4): 258-262. DOI: 10.1159/000516597.
[11]	Auguste A, Gathere S, Pinheiro PS, et al. Heterogeneity in head and neck cancer incidence among black populations from Africa, the Caribbean and the USA: analysis of cancer registry data by the AC3[J]. Cancer Epidemiol, 2021, 75: 102053. DOI: 10.1016/j.canep.2021.102053.
[12]	Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation[J]. Chin J Cancer, 2012, 31(4): 185-196. DOI: 10.5732/cjc.011.10328. pmid: 22313595
[13]	Safavi A, Raad N, Raad N, et al. Epidemiology of nasopharyngeal cancers in Iran: a 6-year report[J]. Asian Pac J Cancer Prev, 2015, 16(10): 4447-4450. DOI: 10.7314/apjcp.2015.16.10.4447.
[14]	Liu Z, Chang ET, Liu Q, et al. Quantification of familial risk of nasopharyngeal carcinoma in a high-incidence area[J]. Cancer, 2017, 123(14): 2716-2725. DOI: 10.1002/cncr.30643. pmid: 28241094
[15]	Bray F, Haugen M, Moger TA, et al. Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(9): 2356-2365. DOI: 10.1158/1055-9965.EPI-08-0461.
[16]	Wu SG, Liao XL, He ZY, et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: a population-based analysis[J]. Oral Oncol, 2017, 73: 83-87. DOI: 10.1016/j.oraloncology.2017.08.006.
[17]	Jia WH, Collins A, Zeng YX, et al. Complex segregation analysis of nasopharyngeal carcinoma in Guangdong, China: evidence for a multifactorial mode of inheritance (complex segregation analysis of NPC in China)[J]. Eur J Hum Genet, 2005, 13(2): 248-252. DOI: 10.1038/sj.ejhg.5201305.
[18]	Liu W, Tang Y, Gao L, et al. Nasopharyngeal carcinoma in children and adolescents—a single institution experience of 158 patients[J]. Radiat Oncol, 2014, 9: 274. DOI: 10.1186/s13014-014-0274-7.
[19]	Sahai P, Mohanti BK, Sharma A, et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy[J]. Pediatr Blood Cancer, 2017, 64(2): 259-266. DOI: 10.1002/pbc.26240. pmid: 27681956
[20]	Feng J, Wang S, Zhang H, et al. Primary nasopharyngeal carcinoma with cerebrospinal fluid EBV positivity: a case report and mini literature review[J]. Infect Med (Beijing), 2024, 3(1): 100089. DOI: 10.1016/j.imj.2024.100089.
[21]	Ziegler P, Reznik AS, Kitchloo SP, et al. Three-dimensional models of the nasopharynx for the study of Epstein-Barr virus infection[J]. Bio Protoc, 2022, 12(6): e4365. DOI: 10.21769/BioProtoc.4365. pmid: 35434197
[22]	Li T, Li F, Guo X, et al. Anti-Epstein-Barr virus BNLF2b for mass screening for nasopharyngeal cancer[J]. N Engl J Med, 2023, 389(9): 808-819. DOI: 10.1056/NEJMoa2301496.
[23]	Li H, Cao D, Li S, et al. Synergistic association of hepatitis B surface antigen and plasma Epstein-Barr virus DNA load on distant metastasis in patients with nasopharyngeal carcinoma[J]. JAMA Netw Open, 2023, 6(2): e2253832. DOI: 10.1001/jamanetworkopen.2022.53832.
[24]	Aldakheel A, Aldehaim M, Alwhaid MS, et al. Locally advanced nasopharyngeal carcinoma in adolescents treated with tomotherapy: experience at King Faisal Specialist Hospital and Research Centre[J]. Ann Saudi Med, 2024, 44(3): 153-160. DOI: 10.5144/0256-4947.2024.153. pmid: 38853474
[25]	Beyene ET, Ketema SG, Alebachew AN, et al. Descriptive epidemiology of nasopharyngeal carcinoma at Tikur Anbessa Hospital, Ethiopia[J]. BMC Cancer, 2021, 21(1): 540. DOI: 10.1186/s12885-021-08311-8.
[26]	Yan Y, Xie C, Di S, et al. Supplemental folic acid and/or multivitamins in pregnancy is associated with a decreased risk of childhood and adolescent nasopharyngeal carcinoma[J]. J Dev Orig Health Dis, 2022, 13(5): 550-555. DOI: 10.1017/S2040174421000635.
[27]	Kara B, Ertan K, Düzova M, et al. Familial clustering of nasopharyngeal carcinoma in the family of an adolescent with nasopharyngeal carcinoma[J]. Turk J Pediatr, 2022, 64(6): 1130-1135. DOI: 10.24953/turkjped.2022.62. pmid: 36583896
[28]	Chang ET, Ye W, Ernberg I, et al. A novel causal model for nasopharyngeal carcinoma[J]. Cancer Causes Control, 2022, 33(7): 1013-1018. DOI: 10.1007/s10552-022-01582-x.
[29]	Wang TM, He YQ, Xue WQ, et al. Whole-exome sequencing study of familial nasopharyngeal carcinoma and its implication for identifying high-risk individuals[J]. J Natl Cancer Inst, 2022, 114(12): 1689-1697. DOI: 10.1093/jnci/djac177.
[30]	Wang S, Ren X, Xue J, et al. Molecular characterization and expression analysis of the squamosa promoter binding protein-like gene family in Paeonia suffruticosa[J]. Plant Cell Rep, 2020, 39(11): 1425-1441. DOI: 10.1007/s00299-020-02573-5.
[31]	Shayah A, Wickstone L, Kershaw E, et al. The role of cross-sectional imaging in suspected nasopharyngeal carcinoma[J]. Ann R Coll Surg Engl, 2019, 101(5): 325-327. DOI: 10.1308/rcsann.2019.0025. pmid: 30855169
[32]	Mui AWL, Lee AWM, Ng WT, et al. Correlations of tumour permeability parameters with apparent diffusion coefficient in nasopharyngeal carcinoma[J]. Phys Imaging Radiat Oncol, 2022, 24: 30-35. DOI: 10.1016/j.phro.2022.09.001.
[33]	中华人民共和国国家卫生健康委员会. 儿童及青少年鼻咽癌诊疗规范(2021年版)[J]. 全科医学临床与教育, 2021, 19(10): 868-873. DOI: 10.13558/j.cnki.issn1672-3686.2021.010.002.
[34]	Chen L, Li J, Li K, et al. Evaluation and analysis of risk factors of hearing impairment for nasopharyngeal carcinoma treated using intensity-modulated radiotherapy[J]. Radiother Oncol, 2024, 190: 109985. DOI: 10.1016/j.radonc.2023.109985.
[35]	Feng Y, Chen X, Cassady K, et al. The role of mTOR inhibitors in hematologic disease: from bench to bedside[J]. Front Oncol, 2020, 10: 611690. DOI: 10.3389/fonc.2020.611690.
[36]	Ben-Ami T, Ash S, Ben-Harosh M, et al. Nasopharyngeal carcinoma in children and young adults-beyond 5-year survival[J]. Pediatr Blood Cancer, 2020, 67(9): e28494. DOI: 10.1002/pbc.28494.
[37]	Kebudi R, Buyukkapu SB, Gorgun O, et al. Nasopharyngeal carcinoma in children: multimodal treatment and long-term outcome of 92 patients in a single center over a 28-year period[J]. Pediatr Blood Cancer, 2021, 68(12): e29372. DOI: 10.1002/pbc.29372.
[38]	Römer T, Franzen S, Kravets H, et al. Multimodal treatment of nasopharyngeal carcinoma in children, adolescents and young adults-extended follow-up of the NPC-2003-GPOH study cohort and patients of the interim cohort[J]. Cancers (Basel), 2022, 14(5): 1261. DOI: 10.3390/cancers14051261.
[39]	Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: radiotherapy dose adaptation after chemotherapy response to minimize late effects[J]. Pediatr Blood Cancer, 2008, 50(4): 849-853. DOI: 10.1002/pbc.21372. pmid: 17973328
[40]	Ben-Ami T. Nasopharyngeal carcinoma in children, current treatment approach[J]. J Pediatr Hematol Oncol, 2024, 46(3): 117-124. DOI: 10.1097/MPH.0000000000002848. pmid: 38447121
[41]	Uezono H, Indelicato DJ, Rotondo RL, et al. Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma[J]. Pediatr Blood Cancer, 2019, 66(12): e27990. DOI: 10.1002/pbc.27990.
[42]	Park SG, Ahn YC, Oh D, et al. Early clinical outcomes of helical tomotherapy/intensity-modulated proton therapy combination in nasopharynx cancer[J]. Cancer Sci, 2019, 110(9): 2867-2874. DOI: 10.1111/cas.14115.
[43]	Luo DH, Li XY, Guo SS, et al. Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage ⅣA-ⅣB childhood nasopharyngeal carcinoma in endemic area: a phase Ⅱ, single-arm trial[J]. Lancet Reg Health West Pac, 2023, 40: 100895. DOI: 10.1016/j.lanwpc.2023.100895.
[44]	Li Y, Tang LQ, Liu LT, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma in children and adolescents: a matched cohort analysis[J]. Cancer Res Treat, 2018, 50(4): 1304-1315. DOI: 10.4143/crt.2017.463. pmid: 29334605
[45]	Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124-1135. DOI: 10.1056/NEJMoa1905287.
[46]	Tang LL, Guo R, Zhang N, et al. Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial[J]. JAMA, 2022, 328(8): 728-736. DOI: 10.1001/jama.2022.13997.
[47]	Casanova M, Bisogno G, Gandola L, et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian rare tumors in pediatric age (TREP) project[J]. Cancer, 2012, 118(10): 2718-2725. DOI: 10.1002/cncr.26528. pmid: 21918965
[48]	Rodriguez-Galindo C, Krailo MD, Krasin MJ, et al. Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: results of the children's oncology group ARAR0331 study[J]. J Clin Oncol, 2019, 37(35): 3369-3376. DOI: 10.1200/JCO.19.01276. pmid: 31553639
[49]	Claude L, Jouglar E, Duverge L, et al. Update in pediatric nasopharyngeal undifferentiated carcinoma[J]. Br J Radiol, 2019, 92(1102): 20190107. DOI: 10.1259/bjr.20190107.
[50]	Kontny U, Franzen S, Behrends U, et al. Diagnosis and treatment of nasopharyngeal carcinoma in children and adolescents-recommenda-tions of the GPOH-NPC study group[J]. Klin Padiatr, 2016, 228(3): 105-112. DOI: 10.1055/s-0041-111180. pmid: 27135270
[51]	袁芳琴, 王藤, 郭文杰, 等. 儿童及青少年鼻咽癌研究进展[J]. 肿瘤学杂志, 2023, 29(8): 704-713. DOI: 10.11735/j.issn.1671-170X.2023.08.B011.
[52]	Zeng Z, Chen C, Guo L, et al. Exploring the optimal chemotherapy strategy for locoregionally advanced children and adolescent nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA level in the era of intensity modulated radiotherapy[J]. Front Oncol, 2020, 10: 600429. DOI: 10.3389/fonc.2020.600429.
[53]	Jin YN, Cao HJ, Gong XH, et al. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?[J]. J Cancer Res Clin Oncol, 2022, 148(10): 2569-2579. DOI: 10.1007/s00432-021-03817-x.
[54]	Chen CY, Lin YS, Chen CH, et al. Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma[J]. J Biomed Sci, 2018, 25(1): 30. DOI: 10.1186/s12929-018-0430-8.
[55]	Adkins DR, Haddad RI. Clinical trial data of anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review[J]. Cancer Treat Rev, 2022, 109: 102428. DOI: 10.1016/j.ctrv.2022.102428.
[56]	Zhao Y, Lee CK, Lin CH, et al. PD-L1: CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways[J]. Immunity, 2019, 51(6): 1059- 1073.e9. DOI: 10.1016/j.immuni.2019.11.003.
[57]	Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 184. DOI: 10.1186/s13046-021-01987-7.
[58]	Que Y, Hu Y, Hong D, et al. Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov[J]. J Immunother Cancer, 2021, 9(9): 34583971. DOI: 10.1136/jitc-2021-002920.
[59]	Hong M, Tang K, Qian J, et al. Immunotherapy for EBV-associated nasopharyngeal carcinoma[J]. Crit Rev Oncog, 2018, 23(3/4): 219-234. DOI: 10.1615/CritRevOncog.2018027528.
[60]	Uno M, Tamaki Y, Burioka H, et al. Early pain relief in malignant psoas syndrome with radiation therapy: a case report[J]. Cureus, 2024, 16(11): e73007. DOI: 10.7759/cureus.73007.
[61]	Nambiar SP, Joseph HB, Satapathy AK, et al. Predictors of quality of life (QOL) and treatment adherence among children with nephrotic syndrome[J]. Family Med Prim Care, 2024, 13(9): 3598-3602. DOI: 10.4103/jfmpc.jfmpc_1825_23.
[62]	Eapen V, Islam R, Azim SI, et al. Factors impacting parental quality of life in preschool children on the autism spectrum[J]. J Autism Dev Disord, 2024, 54(3): 943-954. DOI: 10.1007/s10803-022-05848-w.
[63]	Jin J, Guo SS, Liu LT, et al. Comparison of long-term quality of life and their predictors in survivors between paediatric and adult nasopharyngeal carcinoma in the intensity-modulated radiotherapy era[J]. BMC Cancer, 2024, 24(1): 1223. DOI: 10.1186/s12885-024-12966-4.
[64]	Sinclair AJ, Moalwi MH, Amoaten T. Is EBV associated with breast cancer in specific geographic locations?[J]. Cancers (Basel), 2021, 13(4): 819. DOI: 10.3390/cancers13040819.
[65]	Zheng C, Han L, Wu S. A metabolic investigation of anticancer effect of G. glabra root extract on nasopharyngeal carcinoma cell line, C666-1[J]. Mol Biol Rep, 2019, 46(4): 3857-3864. DOI: 10.1007/s11033-019-04828-1. pmid: 31066003
[66]	Ku TC, Wang PH, Huang JL, et al. The survival outcome of nasopharyngeal cancer patients with traditional Chinese medicine external use: a hospital-based study[J]. J Ethnopharmacol, 2021, 279: 114380. DOI: 10.1016/j.jep.2021.114380.